Bardet-Biedl syndrome (BBS) is a rare ciliopathy — a disorder arising from dysfunction of cilia, the hair-like cellular structures involved in signaling across many organ systems. BBS is invariably characterized by rod-cone dystrophy (a form of retinal degeneration) together with a combination of additional features including obesity, intellectual disability, polydactyly, hypogonadism, and renal anomalies. BBS is a genetically heterogeneous condition with more than 20 recognized subtypes (BBS1 through BBS22 and beyond), each associated with variants in different genes that contribute to ciliary function. Symptoms can first appear from infancy through adulthood depending on the features involved. The exact population prevalence of BBS is not established. This summary reflects clinical data available as of 2026-05-10.

Retinal dystrophy is present in all individuals with BBS and is often among the first features to be recognized. Vision problems typically begin with night blindness, as rod photoreceptors are disproportionately affected early in the disease course. Color vision defects, photophobia, and nystagmus are also frequently observed (30–79% of individuals), and progression to blindness occurs in many affected individuals over time. Abnormal electroretinogram findings are common.

Childhood-onset truncal obesity affects 80–99% of individuals with BBS and is a major management challenge; hypertriglyceridemia and hypertension are frequently associated findings. Neurodevelopmental delay and specific learning disabilities are observed in the majority of individuals, and autism spectrum features and behavioral difficulties are frequently reported. Brachydactyly (shortened fingers or toes) occurs frequently, and postaxial polydactyly is a recognized feature in some subtypes.

Hypogonadism and abnormalities of the genitourinary system are frequent findings. Dental crowding, a high palate, and other oral anomalies have been documented in 30–79% of individuals. Depression and psychiatric symptoms are frequently reported. Not all individuals experience all features, and severity varies considerably.

Bardet-Biedl syndrome results from dysfunction of primary cilia — cellular organelles essential for intercellular signaling during development and in mature tissues. The proteins encoded by BBS-associated genes participate in a multiprotein complex at the base of cilia (the BBSome) that regulates trafficking of signaling molecules. Disruption of ciliary function during development and in post-mitotic cells such as photoreceptors and hypothalamic neurons underlies the multisystem features of BBS. BBS is genetically heterogeneous, with more than 20 numbered subtypes each caused by variants in a distinct gene. The packet does not include specific gene-level data for the umbrella BBS entity, reflecting the broad genetic diversity within this diagnosis. Most cases are identified in childhood or infancy, though some features such as renal disease may become apparent later in life.

Diagnosis of BBS is primarily clinical, based on the presence of the major diagnostic features — rod-cone dystrophy, obesity, intellectual disability, polydactyly, hypogonadism, and renal anomalies. Established clinical criteria require rod-cone dystrophy plus at least three of the other major features, or rod-cone dystrophy with two major features plus at least two minor features such as hepatic fibrosis, diabetes mellitus, dental anomalies, cardiovascular abnormalities, or developmental delay. Molecular genetic testing through multi-gene panel or exome sequencing identifies pathogenic variants and confirms the specific BBS subtype, which can have implications for prognosis and clinical management. Ophthalmological assessment including electroretinography is an essential component of the diagnostic workup. Renal ultrasound, assessment of developmental milestones, and endocrine evaluation for hypogonadism are part of the comprehensive evaluation at diagnosis.

Management of Bardet-Biedl syndrome is multidisciplinary, addressing the multiple organ systems involved. IMCIVREE (setmelanotide) received FDA approval in November 2020 for the treatment of obesity in individuals with BBS. Setmelanotide is a melanocortin-4 receptor agonist that targets a pathway implicated in the hypothalamic dysregulation of appetite and energy metabolism in BBS, providing a targeted pharmacological option for this otherwise refractory feature.

Ophthalmological management focuses on maximizing remaining visual function through low vision aids, orientation and mobility training, and regular monitoring of disease progression. Surgical management of polydactyly is typically performed in infancy or early childhood. Endocrine evaluation and management of hypogonadism, including potential hormone replacement, are part of routine care. Renal function is monitored longitudinally given the frequency of genitourinary anomalies. Nutritional counseling and structured behavioral intervention support weight management alongside pharmacological treatment. Educational and developmental support services address intellectual and behavioral features. Investigational gene therapy approaches targeting specific BBS subtypes are in early-stage development.

Prognosis in Bardet-Biedl syndrome is variable and depends on the specific genetic subtype, the severity of individual features, and the adequacy of multidisciplinary management. Visual impairment is progressive and most individuals experience significant vision loss over time, with blindness occurring in a substantial proportion. Renal disease can progress to end-stage renal failure in some individuals and represents an important long-term complication. Obesity and its metabolic sequelae — including hypertension, hypertriglyceridemia, and diabetes risk — contribute to cardiovascular morbidity. With comprehensive care, including the availability of setmelanotide for obesity management, outcomes have improved. Life expectancy may be reduced in individuals with significant renal or cardiovascular complications, though many individuals with BBS live well into adulthood.

Research in Bardet-Biedl syndrome has accelerated substantially given the growing understanding of ciliary biology and the genetic architecture of BBS. Published literature is dominated by case reports and case series reflecting the rarity and heterogeneity of the condition, supplemented by review articles synthesizing clinical and genetic findings. Gene therapy research is active, with investigational programs targeting BBS1-associated and BBS10-associated disease in early-phase clinical evaluation. The approval of setmelanotide marked the first targeted treatment milestone for BBS and has stimulated interest in melanocortin pathway biology in ciliopathy-associated obesity. Ongoing trials are evaluating additional therapeutic strategies, and the BBS research community continues to characterize the function of novel BBS-associated genes and their roles in ciliary signaling pathways.